Key result
Beta-adrenergic blockers show promise for reducing morbidity and mortality in heart failure by counteracting the deleterious effects of sympathetic activation.
Why the study?
Do beta-adrenergic blockers reduce morbidity and mortality in patients with heart failure?
Population
Patients with heart failure
Design
Review
Authors
Loading...
Hypothesis-generating for beta-blockers in heart failure; leaves clinical efficacy open pending randomized trials.
Do beta-adrenergic blockers reduce morbidity and mortality in patients with heart failure?
This review summarizes the neurohormonal model of heart failure, focusing on the deleterious effects of sympathetic activation and the therapeutic promise of beta-blockers.
Pepper et al. (1999) conducted a review in Heart failure. Beta-adrenergic blockers was evaluated. Beta-adrenergic blockers show promise for reducing morbidity and mortality in heart failure by counteracting the deleterious effects of sympathetic activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: